djohn I agree with you 100%. As with most PPHM supporters it is the science which is so compelling to me. The PS and PE targets are very exciting.Working with the immune system makes great sense. This apparently enables Bavi to work against all solid tumours. And it also seems to work with all anti-cancer drugs. As these drugs become more targeted and thereby less toxic to normal tissue the combinations will only become more tolerable and effective. The latest patents concerning duramycin/PE opens up another whole armory of anti cancer drugs.
Meanwhile I am pleased with the progress of the Cotara and Bavi clinical studies. The results in brain, lung and breast cancers are very impressive. Liver and pancreatic indications are also being studied. I look forward to prostate and ovarian cancers being added to the list. We should soon start to hear reports from these different indications using different combinations.
Will Bavi be able to replace the current SOC immune stimulator that makes the treatment of HCV so intolerable? Will it be tested with Vertex's new drug as well as ribavirin? Don't know...but success in this indication would an unexpected plus...and could be very big.
Entdoc asks some very good questions about the potential of second generation "armed" Bavi. If the first generation works I see the company moving on to the second generstion...and to the duramycin/PE family of drugs.
Don't worry... Big Pharma is watching. There should be a lot of interesting phase II data available in the next 4-12 months.That is what they are waiting for. Good data = Good partnership offers.
Market Data 
Markets 
AI
